GlycoMimetics Croissance future

Future contrôle des critères 0/6

GlycoMimetics devrait augmenter ses bénéfices et ses revenus de 10.5% et de 80.3% par an respectivement, tandis que le BPA devrait croître de croître de 56.2% par an.

Informations clés

10.5%

Taux de croissance des bénéfices

56.2%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.3%
Taux de croissance des recettes	80.3%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	01 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

May 26

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

May 12

GlycoMimetics EPS beats by $0.04

May 03

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Mar 26

GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

Feb 19

GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

Jan 24

How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Dec 28

New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease

Dec 07

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Dec 07

The Investment Case For GlycoMimetics

Nov 17

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:GLYC - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	4	-40	-36	N/A	1
12/31/2025	N/A	-41	-37	N/A	1
12/31/2024	N/A	-43	-38	N/A	1
9/30/2024	0	-40	-35	-35	N/A
6/30/2024	0	-39	-36	-36	N/A
3/31/2024	0	-37	-34	-34	N/A
12/31/2023	0	-37	-35	-35	N/A
9/30/2023	N/A	-38	-35	-35	N/A
6/30/2023	N/A	-37	-35	-35	N/A
3/31/2023	0	-42	-44	-44	N/A
12/31/2022	0	-47	-47	-46	N/A
9/30/2022	0	-54	-51	-51	N/A
6/30/2022	0	-63	-60	-60	N/A
3/31/2022	0	-64	-57	-57	N/A
12/31/2021	1	-63	-58	-57	N/A
9/30/2021	1	-62	-54	-54	N/A
6/30/2021	2	-58	-49	-49	N/A
3/31/2021	2	-58	-50	-50	N/A
12/31/2020	10	-51	-39	-39	N/A
9/30/2020	10	-50	-42	-42	N/A
6/30/2020	9	-50	-44	-44	N/A
3/31/2020	9	-51	-41	-41	N/A
12/31/2019	N/A	-58	-52	-52	N/A
9/30/2019	N/A	-57	-49	-49	N/A
6/30/2019	N/A	-55	-46	-46	N/A
3/31/2019	N/A	-51	-48	-47	N/A
12/31/2018	N/A	-48	-43	-43	N/A
9/30/2018	N/A	-44	-42	-42	N/A
6/30/2018	N/A	-40	N/A	-38	N/A
3/31/2018	N/A	-37	N/A	-31	N/A
12/31/2017	N/A	-33	N/A	-30	N/A
9/30/2017	N/A	-32	N/A	-27	N/A
6/30/2017	0	-32	N/A	-29	N/A
3/31/2017	0	-32	N/A	-30	N/A
12/31/2016	0	-32	N/A	-30	N/A
9/30/2016	0	-32	N/A	-31	N/A
6/30/2016	0	-32	N/A	-10	N/A
3/31/2016	20	-13	N/A	-9	N/A
12/31/2015	20	-13	N/A	-8	N/A
9/30/2015	20	-11	N/A	-7	N/A
6/30/2015	20	-11	N/A	-26	N/A
3/31/2015	15	-13	N/A	-10	N/A
12/31/2014	15	-11	N/A	-4	N/A
9/30/2014	15	-8	N/A	-4	N/A
6/30/2014	15	-5	N/A	-2	N/A
3/31/2014	0	-16	N/A	-14	N/A
12/31/2013	4	-11	N/A	-16	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: GLYC devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: GLYC devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: GLYC devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: GLYC ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: GLYC ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de GLYC devrait être élevé dans 3 ans

GlycoMimetics Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

No longer forecast to breakeven

Price target decreased by 31% to US$5.50

No longer forecast to breakeven

Price target decreased by 35% to US$5.50

Forecast to breakeven in 2025

Price target decreased to US$8.50

Recent updates

Crescent Biopharma, Inc. entered into an acquisition agreement to acquire GlycoMimetics, Inc. (NasdaqGM:GLYC) in a reverse merger transaction.

GlycoMimetics, Inc. Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Glycomimetics Announces to Reduce Its Workforce by Approximately 80%

We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

GlycoMimetics Receives Non-Compliance letter from Nasdaq Regarding Listing Rule 5450(a)(1)

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

New major risk - Financial position

New major risk - Revenue and earnings growth

New minor risk - Profitability

No longer forecast to breakeven

GlycoMimetics, Inc. to Report Q1, 2024 Results on May 09, 2024

GlycoMimetics, Inc., Annual General Meeting, May 01, 2024

New minor risk - Profitability

GlycoMimetics Can Become A Game Changer In Blood Cancers

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

GlycoMimetics, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Price target decreased by 31% to US$5.50

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

GlycoMimetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Senior VP & Chief Medical Officer recently bought US$90k worth of stock

GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

New minor risk - Market cap size

GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

No longer forecast to breakeven

GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee

Price target decreased by 35% to US$5.50

Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Forecast to breakeven in 2025

Chief Medical Officer recently bought US$248k worth of stock

GlycoMimetics, Inc. Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting

Insider recently bought US$53k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021)

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics, Inc. Appoints Edwin Rock as Chief Medical Officer

GlycoMimetics has a new Chief Medical Officer

Second quarter 2022 earnings released: US$0.25 loss per share (vs US$0.28 loss in 2Q 2021)

GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K

GlycoMimetics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Price target decreased to US$8.50

GlycoMimetics Receives a Notice from Nasdaq Regarding Minimum Bid Price Requirement

GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2021)

Insufficient new directors

GlycoMimetics, Inc. to Report Q1, 2022 Results on Apr 28, 2022

GlycoMimetics, Inc., Annual General Meeting, May 18, 2022

GlycoMimetics Positive Data For AML Therapy Increasingly Likely

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

GlycoMimetics, Inc. to Report Q4, 2021 Results on Mar 03, 2022

GlycoMimetics, Inc. Appoints Bruce Johnson as Senior Vice President and Chief Commercial Officer

Insufficient new directors

Insufficient new directors

Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Independent Director recently bought US$82k worth of stock

Price target increased to US$14.50

GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Price target increased to US$14.50

Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients

GlycoMimetics, Inc. Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination with Venetoclax and Azacitidine

GlycoMimetics, Inc.(NasdaqGM:GLYC) dropped from Russell 3000E Value Index

Consensus forecasts updated

GlycoMimetics, Inc. Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

GlycoMimetics EPS beats by $0.04

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation